資料由法律人 LawPlayer整理提供·UK legislation / curated by LawPlayer from legislation.gov.uk
(1) These Regulations may be cited as the Medicines (Products for Animal Use—Fees) Regulations 1997 and shall come into force on 1st July 1997.
(2) These Regulations apply only to fees relating to products for animal use.
(1) In these Regulations, unless the context requires otherwise—
“abridged standard application” means an application for a marketing authorisation, other than a simple application which, by virtue of regulation 4(8) of the 1994 Regulations , need not be accompanied by the results of tests and trials of the type specified in Article 5.10 of Directive 81/851/EEC because the applicant has demonstrated that he is entitled to the benefit of paragraph (a)(i), (ii) or (iii) of that Article;
“ the Act ” means the Medicines Act 1968 ;
“active ingredient” means the ingredient of a product in respect of which efficacy is claimed;
“application for assistance in connection with a mutual recognition application” means a request for the preparation of an assessment report of the type required by virtue of the second paragraph of Article 17.3 of Directive 81/851/EEC in order to make an application to another member State for mutual recognition of a marketing authorisation, or the updating of an existing assessment report for the purpose of enabling such an application to be made, and includes any assistance given of the type specified in Articles 18.2 and 18.3 of that Directive in connection with a subsequent application for mutual recognition in relation to which the assessment report or updated assessment report has been prepared;
“biological product” includes an antigen, toxin, antitoxin, toxoid, serum, antiserum or vaccine or a fraction of any such product;
“complex application” means an application, other than a major application for, or for a variation of, a marketing authorisation or product licence where the application—
relates to a product which is intended to be used in accordance with an indication for use in respect of a different species of animal or as treatment for a new medicinal purpose;
relates to a product containing a new combination of active ingredients which have not previously been included in that combination in a product in respect of which a marketing authorisation or product licence for animal use (other than product licence of right) has previously been granted in the United Kingdom;
relates to a product containing a new adjuvant or a new excipient;
relates to a product which is intended to be administered by a route of administration different from that used in the administration of any product which contains the same active ingredient as the product in question and in respect of which a marketing authorisation or a product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom;
relates to a sterile product the manufacture of which involves a method of sterilisation different from that used in the manufacture of any product which contains the same active ingredient as the product in question and in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom;
relates to a product containing an active ingredient the manufacture of which involves a route of synthesis (or, in the case of a product not synthetically produced, a method of manufacture) different from that used in the manufacture of the active ingredient of any product which contains the same active ingredient as the product in question and in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom;
relates to a biological product containing an active ingredient, the manufacture of which involves a growth substrate different from that used in the manufacture of the active ingredient of any product which contains the same active ingredient as the product in question and in respect of which a marketing authorisation or product licence has previously been granted in the United Kingdom;
relates to a product which is a controlled release preparation and a marketing authorisation or product licence for animal use (other than a product licence of right) for such a preparation constituting the same active ingredient as the product in question has not previously been granted in the United Kingdom;
relates to a sterile product the container of which is directly in contact with the product and is made from different a material from the container of any product which contains the same ingredient as the product in question and in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom;
names as manufacturer of the active ingredient of the product in question a different manufacturer from the manufacturer of the active ingredient of any product which contains the same active ingredient as the product in question and in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom; or
relates to a biological product containing an active ingredient derived from a strain of micro-organism different from that used in the manufacture of the active ingredient of any product which contains the same active ingredient as the product in question and in respect of which a marketing authorisation or product licence has previously been granted in the United Kingdom;
“Directive 81/851/EEC” means Council Directive 81/851/ EEC on the approximation of the laws of the Member States relating to veterinary medicinal products as amended by Council Directives 90/676/EEC and 93/40/EEC and as extended by Directive 90/677/EEC and widened by Directive 92/74/EEC ;
“Directive 90/677/EEC” means Council Directive 90/677/EEC extending the scope of Directive 81/851/EEC on the approximation of the laws of the Member States relating to veterinary medicinal products and laying down additional provisions for immunological veterinary medicinal products;
“Directive 92/74/EEC” means Council Directive 92/74/EEC widening the scope of Directive 81/851/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to veterinary medicinal products and laying down additional provisions on homoeopathic veterinary medicinal products;
“ EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992 as adjusted by the Protocol signed at Brussels on 17th March 1993 and as amended by the Decision of the EEA Joint Committee No. 7/94 ;
“EEA State” means a State which is a Contracting Party to the EEA Agreement other than the United Kingdom;
“emergency vaccines” means vaccines manufactured or assembled only from material obtained from the particular animal, flock or herd intended to be vaccinated in circumstances in which no other suitable authorised or licensed vaccines are readily available for such use;
“immunological Veterinary Medicinal Product” has the same meaning as in the Directive 90/677/EEC;
“major application” means an application for a marketing authorisation or product licence in respect of a product containing a new active ingredient;
“marketing authorisation” means an authorisation to place on the market in the United Kingdom a Veterinary Medicinal Product but shall not include a marketing authorisation granted by the Community in accordance with the provisions of Council Regulation (EEC) No. 2309/93 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products ;
“marketing authorisation (parallel import)” means a marketing authorisation granted by the Ministers in respect of a Veterinary Medicinal Product which is imported into the United Kingdom from another EEA State for which there has been granted a marketing authorisation by an EEA State and which has no different therapeutic effect from a Veterinary Medicinal Product for which a marketing authorisation has already been granted in the United Kingdom;
“medicinal product” includes any substances or article specified in any Order made under—
section 104 or 105(1)(a) of the Act which directs that Part II of the Act shall have effect in relation to such substance or article; or
section 130(3A) of the Act ,
and includes any substance or article to be administered in a medicinal test on animals under section 32(6)(c) of the Act;
“the Ministers” has the meaning given by regulation 1(4) of the 1994 Regulations;
“mutually recognised marketing authorisation” means a marketing authorisation which has been mutually recognised by another member State;
“new active ingredient” means—
an active ingredient that has not previously been included as an active ingredient in a product in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom; or
an active ingredient in a product derived from genetically engineered micro-organisms, recombinant DNA technology or monoclonal antibodies; or
in the case of a biological product, a vaccine of a particular micro-organism whether in a live or inactivated form, other than a vaccine of a particular micro-organism which is derived from a strain of micro-organism which is antigenetically similar to that used in the manufacture of the active ingredient of a product in respect of which a marketing authorisation or product licence (not being a product licence of right) has previously been granted in the United Kingdom;
“new excipient” means any ingredient of a product, other than an active ingredient, that has not previously been included in a product—
which is intended to be administered by the same route of administration as that product; and
in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted in the United Kingdom,
except that, in the case of a product intended to be administered orally, the expression does not include any ingredient specified in any enactment (including an enactment comprised in subordinate legislation) as an approved ingredient or additive—
in food or food products; or
in animal feedingstuffs where the product is intended for administration after being incorporated in the feedingstuff;
“product” means—
a Veterinary Medicinal Product, where it is used solely in relation to an application for, or relating to, a marketing authorisation; and
a medicinal product where it is used solely in relation to any other application;
except that, where it is used in relation to both an application for, or relating to, a marketing authorisation and any other application, it shall mean both a Veterinary Medicinal Product and a medicinal product;
“reference member State” has the meaning given by Article 2.2 of Regulation ( EC ) No. 541/95 ;
“Regulation (EC) No. 541/95 ” means Commission Regulation (EC) No. 541/95 concerning the examination of variations to the terms of a marketing authorisation granted by a competent authority of a Member State;
“the 1994 Regulations” means the Marketing Authorisations for Veterinary Medicinal Products Regulations 1994 ;
“relevant authority” insofar as it is used in relation to a marketing authorisation, or an application for, or relating to, such an authorisation, means the Ministers, and otherwise means the licensing authority;
“simple application” means an application for a marketing authorisation or product licence when the application—
is made by reference to an application for a particular product (“the existing product”) in respect of which a marketing authorisation or product licence for animal use (other than a product licence of right) has previously been granted;
is made by permission of the marketing authorisation or licence holder for the existing product;
relates to a product which is in all the following respects the same as the existing product—
the formulation is identical;
it is intended to be used in accordance with the same indications;
it is intended to be administered by the same route of administration;
the manufacturer named in the application is the same as the manufacturer of the existing product;
the method of manufacture is the same; and
in the case of a sterile product the method of sterilisation is the same and the container which is directly in contact with the product is made from the same material;
“standard application” means an application which is not a major, complex, abridged standard or simple application; and
“Veterinary Medicinal Product” means a veterinary medicinal product of the type specified in Article 1.2 of Directive 81/851/EEC and to which the provisions of that Directive apply.
(2) Other expressions used in these Regulations have, in so far as the context admits, the same meanings as in Directive 81/851/EEC and Regulation (EC) No. 541/95 .
(3) In these Regulations, unless the context otherwise requires—
(a) any reference to a numbered regulation or to a numbered Schedule is a reference to the regulation of or the Schedule to these Regulations so numbered in these Regulations;
(b) any reference in a regulation or a Schedule or Part of a Schedule to a numbered paragraph is a reference to the paragraph so numbered in the regulation or Schedule or Part of a Schedule in which the reference occurs; and
(c) any reference in a Schedule or Part of a Schedule to a lettered table is a reference to the table so lettered in the Schedule or Part of a Schedule in which the reference occurs.
(4) Part 1 of Schedule 1 shall have effect for the purpose of the interpretation of Schedule 1.
Subject to the following provisions of these Regulations, there shall be payable by the applicant in connection with an application for the grant of a marketing authorisation, a product licence, a manufacturer’s licence, a wholesaler dealer’s licence or an animal test certificate the relevant fee prescribed in Part II of Schedule 1.
Subject to the following provisions of these Regulations, there shall be payable by the applicant in connection with an application for assistance in connection with a mutual recognition application the relevant fee prescribed in Part III of Schedule 1.
Subject to the following provisions of these Regulations, there shall be payable by the applicant in connection with an application for the variation of a marketing authorisation, a product licence, a manufacturer’s licence, a wholesale dealer’s licence or an animal test certificate the relevant fee prescribed in Part IV of Schedule 1.
A separate fee shall be payable in respect of each variation of each provision of a marketing authorisation, licence or certificate applied for in any one application except that no separate fee shall be payable in respect of any variation which is related to or is consequential upon another variation of a provision of the same marketing authorisation, licence or certificate in the same application.
No fee shall be payable for a variation made at the express written invitation of the relevant authority.
Subject to the following provisions of these Regulations, in connection with an application for the renewal of a marketing authorisation, a product licence, a manufacturer’s licence or an animal test certificate there shall be payable by the applicant the relevant fee prescribed in Part V of Schedule 1.
Where an applicant applies for renewal of a marketing authorisation, a product licence, a manufacturer’s licence or an animal test certificate so as to contain provisions which are not identical to that marketing authorisation, licence or certificate as in force at the date of that application, there shall be payable by the applicant the renewal fee plus the fee which would have been payable had a separate application been made for each variation.
(1) Subject to the following provisions of these Regulations, in respect of any inspection carried out in connection with an application for the grant, variation or renewal of a manufacturer’s licence there shall be payable by the applicant the relevant fee prescribed in Schedule 2.
(2) Subject to paragraph (4), the holder of a manufacturer’s licence shall pay the relevant fee prescribed in Schedule 2 in respect of any inspection of a site relating to that licence (except for any inspection for which a fee is payable relating to the grant, variation or renewal of a licence).
(3) Where a manufacturing site outside the European Union is specified, and the site is inspected, the fee prescribed in Schedule 2 shall be payable by the marketing authorisation or product licence holder; and if there is more than one marketing authorisation or product licence holder, a fee shall be payable by each marketing authorisation or product licence holder, which shall be the amount prescribed in Schedule 2 divided between the holders of the marketing authorisations or product licences, as the case may be, in proportion to the number of marketing authorisations or product licences held.
(4) No fee shall be payable in respect of any inspection of a site carried out within 6 months of a previous inspection in order to ascertain whether alterations or improvements to the premises concerned, which were required in writing by the relevant authority as the result of that previous inspection, have been implemented.
The holder of any marketing authorisation or product licence shall pay an annual fee calculated in accordance with Schedules 3 and 4 in respect of each calendar year in which he has sold, supplied or manufactured any product to which the marketing authorisation or product licence relates.
The holder of a manufacturer’s licence, other than one specified in paragraph 7(2) of Part II of Schedule 1, shall pay an annual fee of £220 payable on each anniversary of the grant of the licence.
(1) The holder of a wholesale dealer’s licence, other than one specified in paragraph (2), shall pay an annual fee of £440 payable on each anniversary of the grant of the licence.
(2) In the case of the holder of a wholesale dealer’s licence who has a turnover in products of less than £40,000 the annual fee for such a licence, if it is accompanied by a declaration certifying the low turnover, shall be £220 and shall be payable on each anniversary of the grant of the licence.
(3) For the purposes of this regulation, “turnover” means the gross value of all authorised or licensed products sold by way of wholesale dealing by the licence holder in the United Kingdom during the previous calendar year.
(1) Subject to paragraphs (4) and (5), the relevant fee prescribed in Part II of Schedule 5 shall be payable by a person who applies to the Ministers to register a product.
(2) Subject to paragraph (4) a fee of £75 shall be payable by a person who applied to the Ministers to renew the registration of a product.
(3) Subject to paragraph (4) a fee of £85 shall be payable by a person who applies to the Ministers for authorisation to alter an Article 8 dossier relating to a registered product.
(4) No fee shall be payable in connection with the registration of a product, the renewal of a registration of a registered product, or the alteration of an Article 8 dossier relating to a registered product, which is made or carried out at the express written invitation of the Ministers.
(5) The Ministers shall waive or refund payment of any fee otherwise payable under paragraph (1) in the circumstances and to the extent specified in Part III of Schedule 5.
(6) For the purposes of this Regulation the terms—
Article 8 dossier
the Board
the Ministers
product
registered
shall have the meanings respectively given to such terms by regulation 2(1) of the Registration of Homoeopathic Veterinary Medicinal Products Regulations 1997 , as read, in the case of the expression “the Ministers”, with regulation 2(5) of those Regulations and Part I of Schedule 5 shall have effect for the purpose of the interpretation of Schedule 5.
In respect of any reference to the Veterinary Products Committee or to the Medicines Commission—
(a) under section 21 of the Act in connection with a product licence or an animal test certificate; or
(b) under regulation 12(1)(a) of the 1994 Regulations in connection with a marketing authorisation,
there shall be payable by the applicant at the time of the reference, the relevant fee prescribed in Schedule 6.
Any fee payable under these Regulations shall be payable to the Minister of Agriculture, Fisheries and Food within 30 days from the due date following written notice requiring the payment of the fee and all unpaid sums due by way of any fee so payable shall be recoverable as debts due to the Crown.
(1) All fees payable under these Regulations in connection with any application (other than fees for inspections) shall be payable at the time of that application.
(2) If, following either the determination of an application or an inspection, it becomes apparent that—
(a) a lesser fee was properly payable, the excess shall be refunded to the applicant, or as the case may be, the holder of the marketing authorisation, licence or certificate concerned, within 30 days of a request for a refund; or
(b) a higher fee was properly payable, the balance due shall be payable within 30 days following written notice from the relevant authority to the applicant or, as the case may be, the holder of the marketing authorisation, licence or certificate concerned.
(3) All fees for inspections made either in connection with an application or during the currency of a marketing authorisation or licence shall become payable within 30 days of the due date following written notice from the relevant authority.
(1) Where the annual fee for a marketing authorisation or product licence has not been paid by the end of the period of 30 days from the due date, a further fee, calculated in accordance with the provisions of the following paragraphs, shall be payable.
(2) The further fee referred to in the preceding paragraph shall be an amount equivalent to—
(a) 1% of the annual fee payable if payment is made after 30 days and before 61 days;
(b) 2% of the annual fee payable if payment is made after 60 days and before 91 days; and
(c) 5% of the annual fee payable if payment is made after 90 days.
(3) In calculating the sum due under the preceding paragraph the further fee payable shall in all cases be rounded up to the nearest £10.
(4) Where the holder or former holder of a marketing authorisation or product licence has not furnished evidence of his annual turnover in accordance with the provisions of Part I of Schedule 3 so that the annual fee payable cannot be determined before the due date, he may make a payment of an amount on account of the annual fee payable by him (in this regulation referred to as a “payment on account”).
(5) Where the holder or former holder of a marketing authorisation or product licence has made a payment on account in the circumstances mentioned in the preceding paragraph the further fee payable by him shall be calculated as if, in paragraph (2) above, the reference to the annual fee payable were to the difference between the payment on account and the amount of the annual fee as subsequently determined.
(6) In regulations 16 to 18—
(a) “due date” means the date upon which an annual fee became payable following written notice from the relevant authority; and
(b) references to a period calculated from a day are references to the period inclusive of that day.
Where any sum due by way of, or on account of, any fee or any part thereof payable under these Regulations remains unpaid by the holder of a licence or certificate, the relevant authority may serve a notice on him requiring payment of the sum unpaid and, if after a period of one month from the date of service of such notice, or such longer period as the relevant authority may allow, the said sum remains unpaid, the relevant authority may forthwith suspend the licence or certificate until such sum has been paid.
The relevant authority may waive payment of any fee, reduce any fee or part of a fee otherwise payable under these Regulations or refund the whole or part of any fee already so paid in exceptional circumstances or in any of the circumstances specified in Schedule 7.
(1) Subject to paragraph (2), the following Regulations are hereby revoked—
(a) the Medicines (Products for Animal Use—Fees) Regulations 1995 ;
(b) the Medicines (Products for Animal Use—Fees) (Amendment) Regulations 1996 ; and
(c) the Registration of Homoeopathic Veterinary Medicinal Products (Fees) Regulations 1996 .
(2) Paragraph (1) shall not affect—
(a) any notice given or any suspension made under those Regulations and any such notice or suspension shall have effect as if given or made under these Regulations; and
(b) any proceedings instituted under those Regulations.
(1) Subject to paragraphs (2), (3) and (4), these Regulations shall not apply to any application made before the date these Regulations come into force.
(2) A fee shall be payable in respect of any inspection made or any product testing required after the date these Regulations come into force in connection with any application made before that date as if these Regulations applied to that application.
(3) Where an application to renew a marketing authorisation, licence or certificate is made before the date these Regulations come into force, and the authorisation, licence or certificate is due to expire on or after that date the fee shall be that payable under these Regulations, and the balance due shall be payable within 30 days following written notice from the relevant authority.
(4) Nothing in these Regulations shall have effect in relation to an annual fee relating to a calendar year earlier than 1996.
Subject to paragraphs 2, 3, 4 and 5—
(a) the fee for an application for a type A marketing authorisation of the kind described in column (1) of Table A shall be the fee specified in the corresponding entry of column (2) of that Table;
(b) the fee for an application for a type B marketing authorisation of the kind described in column (1) of Table A shall be the fee specified in the corresponding entry of column (3) of that Table; and
(c) the fee for an application for a product licence of the kind described in column (1) of Table A shall be the fee specified in the corresponding entry in column (4) of that Table.
Subject to paragraph 3, 4 and 5, where an application for assistance in connection with a mutual recognition application of a kind described in column (1) of Table C is made within six months after the grant of the marketing authorisation to which it relates, and such application relates to an application for mutual recognition to be made to not more than five member States, the fee for such application shall be fee specified in the corresponding entry in column (2) of that Table.
The fee for a complex application for the variation of—
(a) a marketing authorisation, other than a mutually recognised marketing authorisation, or
(b) a product licence,
shall be £2,640
Subject to paragraph 4, the fee for an application for the renewal of a marketing authorisation of product licence that—
(a) relates solely to an emergency vaccine shall be £40,
(b) relates to a herbal product shall be £300, and
in any other case shall be £1,005.
The fee for an application for an Article 15.2 marketing authorisation of the kind described in column (1) of Table B shall be the fee specified in the corresponding entry in column (2) of that Table.
Where an application for assistance in connection with a mutual recognition application of a kind described in column (1) of Table C is made within six months after the grant of the marketing authorisation to which it relates, and such application relates to an application of mutual recognition to be made to more than five member States, the fee for such application shall be the fee specified in the corresponding entry in column (2) of Table C, plus the additional fee specified in the corresponding entry in column (3) of that Table for the sixth and each additional member State.
The fee for an application of the kind described in column (1) of Table E for the variation of—
(a) a marketing authorisation, other than a mutually recognised marketing authorisation; or
(b) a product licence,
other than a complex application shall be that specified in the corresponding entry in column (2) of that Table.
The fee for an application for a renewal of a manufacturer’s licence referred to in paragraph 7(2) of Part II of this Schedule, shall be £105.
Where an application for a marketing authorisation is made by a person who is already the holder of an Article 15.2 marketing authorisation relating to the same Veterinary Medicinal Product as the marketing authorisation applied for the fee shall be—
(a) where a major application was previously made in respect of the Article 15.2 marketing authorisation, £6,340; and
(b) where a complex application was previously made in respect of the Article 15.2 marketing authorisation, £4,980.
Where an application for assistance in connection with a mutual recognition application is made within six months after the grant of the marketing authorisation to which it relates, and an application or applications for assistance to mutually recognise such authorisation(s) has or have previously been made by the applicant, no fee shall be payable in respect of the new application if the total number of member States to which the previous application or applications and the new application relate does not exceed five.
The fee for an application for the variation of a mutually recognised marketing authorisation of a kind described in column (1) of Table F shall be that specified in the corresponding entry in column (2) of that Table where the United Kingdom is acting as the reference member State and that specified in the corresponding entry in column (3) of the said Table where the United Kingdom is not acting as the reference member State—
The fee for an application for renewal of an animal test certificate shall be £90.
Where—
(a) a major or a complex application is made by a person who is already the holder of an animal test certificate, in respect of a product containing the same active ingredient as the product in respect of which the marketing authorisation or product licence is applied for, or
(b) a major or a complex application is made by a person who is already the holder of a product licence (export only), relating to the same product as the marketing authorisation or product licence applied for,
the fee shall be reduced by the amount of the fee paid in connection with the application for that certificate or licence.
(1) Where an application for assistance in connection with a mutual recognition application of a kind described in column (1) of Table C is made within six months after the grant of the marketing authorisation to which it relates, and—
(a) an application or applications for assistance mutually to recognise such authorisation has or have previously been made by the applicant; and
(b) the total number of member States to which the previous application or applications related does not exceed five but the total number of member States to which the previous application or applications related and the new application relates will exceed five,
a fee calculated in accordance with paragraph (2) shall be payable in connection with the new application.
(2) The fee payable in connection with an application to which subparagraph (1) applies shall be calculated by taking the total number of member States to which the previous application or applications related and the new application relates, deducting five from that number, and by then multiplying the resulting number by the fee specified in the corresponding entry in column (3) of Table C.
The fee for an application for variation of a manufacturer’s licence—
(a) in the case of a manufacturer’s licence referred to in paragraph 7(2) of Part II of this Schedule, shall be £95;
(b) in any other case—
(i) requiring veterinary, scientific or pharmaceutical assessment, shall be £360; and
(ii) not requiring veterinary, scientific or pharmaceutical assessment, shall be £120.
Where an Article 15.2 marketing authorisation is renewed, no fee shall be payable in respect of the first annual renewal.
(1) Subject to sub-paragraphs (2) and (3) and the original application for a marketing authorisation or product licence received at any time before grant containing the active ingredient being granted, where an application for a marketing authorisation or product licence consists of an application for more than one such product containing the same active ingredient or combination of ingredients, the fee shall be of an amount equal to the aggregate of the amounts payable under paragraph 1 in respect of separate applications for each such authorisation or licence but where an original application is withdrawn and a subsequent application for more than one such product proceeds in place of the original application, then an additional fee shall be payable on that subsequent application equal to the difference between the amount paid on that application and that payable for a major application.
(2) If the application is a major application, the fee shall be the amount payable in respect of a major application under paragraph 1 plus—
(a) in respect of each additional marketing authorisation or product licence applied for which relates to a product of a different dosage form, the amount payable in respect of a complex application under paragraph 1; and
(b) in respect of each additional marketing authorisation or product licence applied for which relates to a product of the same dosage form but of a different strength of active ingredient or different combination of active ingredients, the amount payable in respect of a standard application under paragraph 1.
(3) If the application is a complex application, the amount payable shall be the amount payable in respect of a complex application under paragraph 1 plus—
(a) in respect of each additional marketing authorisation or product licence applied for which relates to a product of a different dosage form, the amount payable in respect of a standard application under paragraph 1; and
(b) in respect of each additional marketing authorisation or product licence applied for which relates to a product of the same dosage form but of a different strength of active ingredient or different combination of active ingredients, the amount payable in respect of a simple application under paragraph 1.
Where an application for assistance in connection with a mutual recognition application of a kind described in column (1) of Table C is made within six months after the grant of the marketing authorisation to which it relates, and
(a) an application or applications for assistance to mutually recognise such authorisation has or have previously been made by the applicant; and
(b) the total number of member States to which the previous application or applications related exceeds five, the fee payable in connection with the new application shall be calculated by multiplying the number of member States to which the new application relates by the fee specified in the corresponding entry in column (3) of that Table.
The fee for an application for variation of a wholesale dealer’s licence—
(a) requiring veterinary, scientific or pharmaceutical assessment, shall be £360; and
(b) not requiring veterinary, scientific or pharmaceutical assessment, shall be £120.
The fee for an application for an animal test certificate in relation to a medicinal product, other than a non-food or biological product, which is for administration to food-producing animals shall be £600, and in any other case shall be £250.
(1) Where an application for assistance in connection with a mutual recognition application of a kind described in column (1) of Table D is made more than six months after the grant of the marketing authorisation to which it relates, and such application relates to an application for mutual recognition to be made to not more than five member States, the fee for such application shall be the fee specified in the corresponding entry in column (2) of Table D.
(2) Where an application for assistance in connection with a mutual recognition application of a kind described in column (1) of Table D is made more than six months after the grant of the marketing authorisation to which it relates, and such application relates to an application for mutual recognition to be made to more than five member States, the fee for such application shall be the fee specified in the corresponding entry in column (2) of Table D plus, for the sixth and each additional member State, the fee specified in the corresponding entry in column (3) of that Table.
The fee for an application for the variation of an animal test certificate shall be £200.
(1) The fee for an application for a manufacturer’s licence shall be—
(a) in a case to which sub-paragraph (2) below applies, £95; or
(b) in any other case £2,085; and
(c) in either case, if appropriate, a fee calculated in accordance with Schedule 2 in respect of any inspection made in connection with that application.
(2) This paragraph applies in the case of an application for a manufacturer’s licence which is limited solely to the manufacturer or assembly of—
(a) products the same or supply of which do not require a marketing authorisation or product licence and to which article 2(2)(i) of the Medicines (Exemption from Licences) (Special and Transitional Cases) Order 1971 applies; or
(b) emergency vaccines.
(1) Subject to sub-paragraph (2) below the fee for an application for a wholesale dealer’s licence shall be £1,420.
(2) In the case of a wholesale dealer who has a turnover in respect of products of less than £40,000 the fee payable in connection with an application for a wholesale dealer’s licence, if accompanied by a declaration of turnover, shall be £480.
(3) For the purposes of paragraph 8(2), “turnover” means the gross value of all products sold by way of wholesale dealing by the applicant in the United Kingdom during the previous calendar year. Products sold by way of wholesale dealing by the marketing authorisation or licence holder shall comprise only those products in respect of which an authorisation or a licence is held during the whole or part of that calendar year.
The fee for an application for a marketing authorisation (parallel import) shall be £1,415.
(1) In this Schedule—
“dormant biological product” means a product which is not currently being manufactured or sold and in respect of which there is no current intention to recommence the manufacture or sale;
“major inspection” means an inspection at a site at which 60 or more, but fewer than 250, relevant persons are employed;
“minor inspection” means an inspection at a site at which fewer than 10 relevant persons are employed;
“relevant person” means any person directly or indirectly engaged in, or assisting in, the manufacture or assembly of products and also includes any person connected with such production who is involved in management, quality control, site maintenance, packing, storage or distribution;
“standard inspection” means an inspection at a site at which 10 or more, but fewer than 60, relevant persons are employed; and
“supersite inspection” means an inspection at a site at which 250 or more relevant persons are employed;
(2) In calculating the number of relevant persons for the purposes of this Schedule, any person partly engaged or assisting in the manufacture or assembly of products (whether as a part-time employee or by virtue of being only partly employed in such work) shall be included in the calculation but only as a fraction calculated by reference to the amount of time spent by that person engaged or assisting in the manufacture or assembly of such products or, where such a calculation is inappropriate, by reference to the percentage of his job which related to the manufacture or assembly of such products and, in either case, by comparison with the average working week of a relevant person engaged in full-time employment at the same site.
(1) Subject to paragraphs 3 to 5, except in the case of an inspection falling within sub-paragraphs (2) to (4) below, the fee payable in respect of an inspection of a kind described in column (1) of Table A shall be that specified in the corresponding entry in column (2) of that Table.
(2) Where the site inspected is wholly or partly concerned with the manufacture of sterile products or the filling of the containers directly in contact with such products the fee payable for an inspection of a kind described in column (1) of Table B of such a site shall be that specified in the corresponding entry in column (2) of that Table.
(3) Except in the case of an inspection falling within sub-paragraph (2) above or sub-paragraph (4) below, where the site inspected is concerned only with the assembly of products the fee payable for an inspection of the kind described in column (1) of Table C of such a site shall be that specified in the corresponding entry in column (2) of that Table.
(4) Where the site inspected is limited solely to the manufacture or assembly of—
(a) products, the sale or supply of which do not require a marketing authorisation or product licence and to which article 2(2)(i) of the Medicines (Exemption from Licences) (Special and Transitional Cases) Order 1971 applies, the fee payable shall be £100; and
(b) emergency vaccines, the fee payable shall be £100.
If, following an inspection, it becomes apparent that the inspection fell into a different category from that established by the applicant or the holder of the marketing authorisation or licence, the fee payable under these Regulations in respect of that inspection shall be the fee payable in respect of an inspection falling within the category into which the inspection should have fallen.
The Medicines (Products for Animal Use—Fees) Regulations 1997 (legislation.gov.uk, OGL v3.0). Retrieved via LawPlayer, https://lawplayer.com/uk/act/uksi-1997-1469
Contains public sector information licensed under the Open Government Licence v3.0.
本頁資料來源：legislation.gov.uk (The National Archives)·整理提供：法律人 LawPlayer· lawplayer.com